FDA Approves GSK’s Nucala for Children with Severe Eosinophilic Asthma

, , , , , , ,

The FDA greenlit GlaxoSmithKline’s Nucala (mepolizumab) for treating severe eosinophilic asthma in children as young as 6 years.

Read more
/by